Page Tools:

2018 Oncology Nursing Drug Handbook

Author(s): Gail M. Wilkes, MS, APRN-BC, AOCN, Oncology Nursing Consultant, Kilauea, Hawaii
Margaret Barton-Burke, PhD, RN, FAAN, Director, Nursing Research, Memorial Sloan Kettering Cancer Center
  • ISBN-13: 9781284143508
  • Paperback    1712 pages      © 2018
Price: $99.95 US List
Add to Cart Request a Review Copy

Written especially for nurses caring for patients with cancer, the 2018 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

Completely revised and updated, the 2018 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.

New drugs include: avelumab (Bavencio), brigatinib (Alunbrig), durvalumab (Imfinzi), enasidenib (Idhifa), metronidazole hydrochloride (Flagyl), midostaurin (Rydapt), neratinib (Nerlynx), niraparib (Zejula), olaratumab (Lartruvo), ribociclib (Kisqali), rituximab and hyaluronidase human injection (Rituxan Hycela injection), rucaparib (Rubraca), telotristat ethyl (Xermelo), and tisagenlecleucel (Kymriah).

Take 2018 Oncology Nursing Drug Handbook wherever you go with an affordably priced app for Android and iPhone and iPad. Try the app free for 30 days!

Applicable Courses

Oncology Nursing

Section  1  Cancer Treatment
Chapter  1  Introduction to Chemotherapy Drugs
Chapter  2  Cytoprotective Agents
Chapter  3  Molecular Targeted Therapy
Chapter  4  Immunologic Targeted Therapy
Chapter  5  Chemobiotherapy for Noncancer Diseases
Section  2  Symptom Management
Chapter  6  Pain
Chapter  7  Nausea and Vomiting
Chapter  8  Anorexia and Cachexia
Chapter  9  Anxiety and Depression
Section  3  Complications
Chapter  10  Managing Tumor-Related Skeletal Events and Hypercalcemia
Chapter  11  Infection
Chapter  12  Constipation
Chapter  13  Diarrhea
Appendix  1  Occupational Exposure to Hazardous Drugs
Appendix  2  Common Terminology Criteria for Adverse Events (CTCAE)

Gail M. Wilkes, MS, APRN-BC, AOCN-Oncology Nursing Consultant, Kilauea, Hawaii

Gail M Wilkes, MS, APRN-BC, AOCN
Oncology Nursing Consultant
Kilauea, Hawaii
Additional Titles by this Author

Margaret Barton-Burke, PhD, RN, FAAN-Director, Nursing Research, Memorial Sloan Kettering Cancer Center

This site uses cookies to store information on your computer. Some are essential to make our site work; others help us improve the user experience or allow us to communicate with you effectively. By using this site, you consent to the placement of these cookies. Read our cookie policy to learn more.

Agree & Dismiss